The 3rd Annual Evidence 360 Summit — RWE, Market Access & Pricing, hosted by Veridon Global, will take place on 11–12 March 2027 in Basel, Switzerland, uniting senior decision-makers from pharma, biotech, RWE, HEOR, HTAs, payers, pricing & reimbursement, academia and technology to align evidence generation with real-world access outcomes.

A Strategic Shift: From Silos to an Integrated Evidence-to-Access Journey

This year’s edition moves beyond treating Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR), Market Access and Pricing as isolated functions. Instead, the summit explores how these disciplines align across the full product lifecycle — from early development and launch planning through reimbursement negotiations and post-launch evidence generation. This integrated approach reflects growing industry recognition that successful market access depends on coherent, cross-functional evidence strategies rather than fragmented, late-stage efforts.

Why Basel? Europe’s Pharma and Access Hub

Following the successful 2026 London edition, Veridon Global has relocated the Evidence 360 Summit to Basel — the heart of the European pharmaceutical and biotech ecosystem. Basel hosts major global pharma headquarters, leading HEOR and market access teams, HTA experts and innovative technology partners, creating an ideal environment for high-level dialogue on evidence and access strategy. The co-location with the Immuno-Oncology & Biomarker Summit on the same dates further amplifies opportunities for cross-disciplinary learning and networking.

Who Will Attend?

The summit is designed for senior leaders and practitioners across the evidence-to-access continuum, including:

• Pharma and biotech executives in market access, pricing, HEOR and RWE
• HTA body representatives and health technology assessment experts
• Payers and reimbursement decision-makers
• Pricing and market access strategists
• Academia and research organisations generating real-world data
• Technology companies enabling RWE generation, data analytics and value demonstration

This diverse stakeholder mix ensures discussions reflect both payer expectations and industry realities, fostering practical solutions that bridge evidence generation and access outcomes.

Core Themes: Evolving European Evidence Requirements

Key discussions at the 2027 summit will examine the rapidly changing European landscape for evidence generation and market access, including:

Evolving HTA practices: Preparation for EU Joint Clinical Assessments (JCA), harmonisation of national HTA requirements and the impact on evidence planning

• Demand for comparative RWE: Payer expectations for head-to-head effectiveness data, indirect treatment comparisons and real-world benchmarking against standard of care
• Value demonstration beyond clinical endpoints: Incorporating patient-reported outcomes, quality-of-life data, caregiver burden and societal value into reimbursement dossiers
• Early evidence integration: Aligning RWE and HEOR strategies from Phase II onwards to de-risk launch and support faster, broader access

These themes reflect lessons from recent European access challenges, where fragmented evidence strategies have led to delayed reimbursements, restricted indications and suboptimal pricing outcomes.

Practical Focus: From Evidence Design to Access Outcomes

A defining feature of the Evidence 360 Summit is its emphasis on actionable insights rather than theoretical discussions. The agenda will feature:

Practical pharma case studies demonstrating how integrated evidence strategies have secured favourable pricing, broad reimbursement or accelerated access in key European markets

• Payer and HTA perspectives offering direct insight into what decision-makers expect from RWE, HEOR and value dossiers
• Interactive panel discussions enabling attendees to challenge assumptions, share experiences and co-develop solutions to common access barriers
• Expert-led sessions connecting stakeholders across the entire evidence-to-access journey — from clinical development teams to market access and commercial leaders

This format helps teams design, evaluate and leverage evidence to directly influence pricing, reimbursement and patient access decisions.

Expected Session Topics

While the full 2027 agenda is still being finalised, previous editions and related European access events point to several high-priority topics likely to feature:

RWE Strategy and Generation

• Designing fit-for-purpose RWE studies for HTA and payer submissions
• Leveraging real-world data for indication expansion and label updates
• Addressing data quality, bias and generalisability concerns in RWE
• Integrating RWE with clinical trial evidence for robust value narratives

HEOR and Value Demonstration

• Building economic models that resonate with European HTA bodies
• Incorporating patient-centric outcomes and societal value into cost-effectiveness analyses
• Early HEOR planning to inform clinical development and target product profiles
• Adapting value dossiers for country-specific HTA requirements across Europe

Market Access and Pricing

• Navigating EU JCA and its implications for evidence generation timelines
• Pricing strategies in the face of increasing cost-containment pressures
• Managed entry agreements, outcomes-based contracts and risk-sharing schemes
• Post-launch evidence plans to sustain reimbursement and support price maintenance

Cross-Functional Alignment

• Breaking down silos between clinical development, HEOR, market access and commercial teams
• Creating evidence master plans that span pre-launch to post-launch phases
• Engaging payers and HTAs early to shape evidence expectations
• Leveraging technology and data partnerships to accelerate evidence generation

Registration and Participation at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/registration/

Organised by Veridon Global, the Evidence 360 Summit is positioned as a must-attend event for senior professionals seeking to stay ahead in the rapidly evolving European evidence and access landscape. The small-scale, high-interaction format makes it particularly valuable for those looking to benchmark strategies, learn from real-world case studies or establish partnerships that strengthen evidence-to-access capabilities.

For organisations active in pharmaceutical development, HEOR, RWE or market access, the 3rd Annual Evidence 360 Summit in Basel offers a focused, high-value platform to shape the future of evidence-driven patient access.